In 1996, Honnorat et al. found that the CV2 antibody was specific for oligodendrocytes and considered that the target antigen was CRMP3 (66 kDa); they were the first to clarify the relationship between CV2 and paraneoplastic neurologic syndrome (PNS) (5). The gene discussed is DPYSL4; the disease is paraneoplastic neurologic syndrome.